Kroeger Christopher A. 4

What Happened
Christopher A. Kroeger, CEO of MapLight Therapeutics (MPLT), reported multiple open‑market sales totaling 68,491 shares between May 7 and May 11, 2026, for aggregate proceeds of approximately $1,949,635. Major lots included 29,624 shares on May 8 ($814,068), 14,880 shares on May 7 ($423,634), and 6,871 shares on May 11 (~$206,405). All reported dispositions are sales (S) — routine sales reduce holdings rather than a purchase that would signal added insider exposure.

Key Details

• Transaction dates: May 7, May 8 and May 11, 2026.
• Reported per‑lot (examples): 14,880 @ $28.47 ($423,634); 29,624 @ $27.48 ($814,068); 6,871 @ $30.04 ($206,405); other lots at prices between ~$27.48 and $30.56 (filing reports weighted averages; footnotes show more detailed price ranges).
• Total shares sold: 68,491. Total proceeds: ≈ $1,949,635.
• Shares held after transaction: Not specified in the material provided in this summary (check the Form 4 for Column 9 balance).
• Notable footnotes: At least some sales were made pursuant to a Rule 10b5‑1 trading plan adopted Dec 29, 2025 (F1). Several entries report weighted‑average prices and disclose that the shares were sold in multiple trades at ranges (see footnotes F2–F10). F11 notes shares are held by the C&M Kroeger Nominee Trust, of which the reporting person is co‑trustee with voting and dispositive power.
• Filing timeliness: Form filed May 11, 2026 — covering trades through May 11 — appears timely under standard Form 4 reporting rules (no late‑filing flag was indicated).

Context

• Sales under a Rule 10b5‑1 plan are pre‑arranged and are often used to systematically sell shares; such sales are not, by themselves, proof of a change in the insider’s view of the company.
• For retail investors, purchases by insiders tend to carry more weight as a bullish signal; disclosed sales may be for diversification, tax, or personal-liquidity reasons.
• The filing includes weighted‑average prices and offers to provide per‑trade price breakdowns on request (per footnotes), so review the full Form 4 if you need transaction‑by‑transaction pricing or the post‑transaction holding balance.